The Effect of Infusion 125I-antiAFP Antibody via Hepatic Artery Combined with Chemo-embolization in Patients with Hepatocellular Carcinoma

Objective To evaluate the hysteresis of 125Ⅰ-antiAFP antibody infused via hepatic artery combined with TACE in patients with HCC,and the effect and toxicity were observed. Methods In targetting therapy group (36 cases),125Ⅰ-antiAFP antibody was given as an intrahepatic artery infusion combined with TACE.34 cases reseived TACE alone group. Results Medium radioactive ratio of tumor/liver was 1.86±0.72 after targetting therapy.Response rate (PR+MR) were 55.6% and 41.2% for targetting therapy group and TACE alone group,respectively (P＞0.05).Markedly reduced rate of serm AFP level and medium duration of response were 77.8% and 8.5%M for targetting therapy group and 52.9% and 5.6M for TACE alone group,respectively (P＜0.05).Transient hypothyronine T3 and T4 occurred in 16.7% cases of targetting therapy group.The other toxicities were tolerable and similar in two groups. Conclusion 125Ⅰ-antiAFP antibody infusion via hepatic artery combined with TACE have a specific retentionist in the tumor mass.The efficacies of complex therapy were better than TACE alone for HCC,and the toxicities were tolerable.